+34 679 490 537info@nanbiosis.com

Nanbiosis

Polyurethane and polyurea nanoparticle (PUUa), improves cancer therapy

The national consortium led by the research group of Addressing and Drug Release CIBBIM – Nanomedicine of the Vall d’Hebron Research Institute (VHIR) and led by Dr. Ibane Abasolo, Scientific Coordinataror of Unit 20 of NANBIOSIS, has shown improvement in the effectiveness and specificity of targeted therapy against cancer through the use of polyurethane-polyurea nanocapsules (PUUa), a nanoparticle with a proven targeted release, very useful for drugs with a high level of toxicity and low specificity of distribution. This nanoparticle has been developed by the research section of the Catalan company EcopolTech and Unit 20 of ICTS Nanbiosis has participated in vivo nanoparticle biodistribution assays, following the tissue accumulations of fluorescently labeled nanoparticles by means of the IVIS-Spectrum equipment. 

The study was based on the encapsulation of the drug Plitidepsin produced and patented by the Spanish pharmaceutical company PharmaMar SA. This drug, which was found in a marine invertebrate of Mediterranean origin and has proven efficacy in laboratory studies, also has a hydrophobic nature that makes its use in humans difficult. The nanoparticle PUUa, by covering the drug, improves biodistribution and reduces the toxicity of the drug, in addition to dramatically reducing the concentration necessary for its therapeutic function. Thus, it potentially increases the use of Plitidepsin in therapy for several types of cancer.
The nanocapsule is based on a shell made of, an RGD peptide to direct the nanoparticles to tumor cells and other fractions that ensure that the drug is released in environments with a high content of glutathione, a molecule that is found in high concentrations inside the tumor cells. Once inside the cell, the drug content is released and therapeutic function begins, highly effective in glioblastoma, colorectal cancer and breast cancer.

The research and synthesis of this nanocapsule has been carried out in collaboration with the Biomedical Research Institute, the CIBBER-BBN, and the companies Ecopol Tech SL and PharmaMar SA.

The importance of nanomedicine in cancer therapy:
In nanomedicine, a nanocapsule refers to an organic and biodegradable nanometric container that contains other molecules inside it, to be released once they reach their destination. In the case of cancer treatment, nanocapsules contain drugs that are usually hydrophobic and if they are administered naked (or without being wrapped by the nanocapsule), they are vulnerable to detection and digestion by macrophages – which reduces the effective accumulation of the drug in the tumor cells-, in addition to presenting a high toxicity both for the tumor cells of interest and for the healthy cells of the individual. These immunological barriers cause the administration at high concentrations of the drug chosen for the therapy, which leads to the known side effects of chemotherapy and the appearance of resistance.

Encapsulation can solve these problems: it prevents the elimination of drugs by macrophages, they circulate for a longer time through the blood flow, and they have improved permeability and retention. All because they are more specific covers and less toxic to the human body. Some of these nanomedicines are already being used in oncological patients, such as Myocet ™, DaunoXome ™, Depocyt ™, Abraxane ™, Genexol- * PM ™, and more recently, Onivyde ™: and all have improved the survival of cancer patients in a significative way.

And the research goes further, since the CIBBIM – Nanomedicine Pharmacological Surveillance and Release group of the VHIR has been working for ten years to bring the nanomedicines in development closer to patients and is currently working on several European projects in which several studies are being studied. nanoparticles for the treatment of pancreatic cancer, colorectal and breast cancer, Ewing sarcoma and Fabry minority disease.

Read More

Conxita Solans receives the lectureship award of the Japan Research Institute of Materials Technology

Prof. Conxita Solans (Nanostructured liquid characterization unit 12 of NANBIOSIS) received the lectureship award of the Japan Research Institute of Materials Technology from Prof. Masahiko Abe, Director of the Institute. Prof. Solans delivered her lecture during the meeting held in Noda (Japan) on December 1st, 2017.

Read More

Graphene transistors as eficient transducers for electrocorticography

Researchers of Micro-Nano Technologies Unit (U8) of NANBIOSIS, are co-authors of a new paper published in Advanced Functional Materials. Neuroelectronic interfaces bridge the central nervous system to the outside world and hold great potential for functional restoration in persons with paralysis, other forms of motor dysfunction, or limb loss. Neuroscientists and neurosurgeons are thus looking for technologies that could ideally record the whole brain with a high spatial and temporal resolution. Electrocorticography (ECoG), the practice of placing arrays of large-diameter electrodes (few millimeters) directly on the cortex is the current clinical solution to obtaining brain recordings with high temporal resolution.

Recent research from the CIBER-BBN and  IMB-CNM Biomedical Applications group (IP Rosa Villa)  coordinator of NANBIOSIS Unit 8, in collaboration with ICN2 (IP JA Garrido) , IDIBAPS  (IP MV Sanchez Vives) and INSERM (IP B Yvert) groups,  has focused on the development of graphene technology for electrocorticography. Specifically, flexible graphene transistor arrays have been fabricated and applied to the in vivo measurement of local field potentials.

Graphene is one of the most promising material candidates for neural interfacing thanks to its biocompatibility, low dimensionality and mechanical properties. Additionally, graphene exhibits extraordinary electrical properties such as high carrier mobility and chemical stability, features that only few materials can offer therefore helping to create a very intimate interface between the tissue and the transducing system.

However, previous in vivo studies using single layer CVD graphene have used an electrode configuration. Instead, here they propose the use of a transistor configuration. The main reason for this choice is certainly the local preamplification inherent to a transistor. As a consequence, less environmental noise is picked by the device.

Their work presents a complete description of the fabrication technology, the operation of graphene solution-gated field-effect transistors (SGFET) in saline solution and of the custom characterization electronic system. The devices are finally used in in vivo experiments in which the transconductance and noise are first characterized during slow-wave activity followed by the recording of visual and auditory evoked activity as well as of synchronous activity in a rat model of epilepsy. An in-depth comparison of the signal-to-noise ratio of graphene SGFETs with that of platinum black electrodes confirms that graphene SGFET technology is approaching the performance of state-of-the art neural technologies.

Full details of the fabrication, characterization and in vivo performance of the flexible graphene transistor probes can be found in the paper below.

Hébert, C., et al., Flexible Graphene Solution‐Gated Field‐Effect Transistors: Efficient Transducers for Micro‐Electrocorticography. Advanced Functional Materials, 2017.

Read More

MATERPLAT Launches the document “Spanish Technological Strategy of Advanced Materials and Nanomaterials – MATERPLAT”

MATERPLAT, the Technological Platform of Advanced Materials and Nanomaterials, has presented the “Spanish technological strategy of advanced materials and nanomaterials” in whose preparation NANBIOSIS has participated. This document seeks to collect and reflect the technological challenges, needs and barriers associated with industrial sectors that clearly require innovation in advanced materials, as well as in their processes and / or products, to ensure their competitiveness, sustainability and growth.

For further information:

 

Read More

The Minimally Invasive Surgery Centre uses HoloLens glasses for medical training and surgical assistance in urology

The Minimally Invasive Surgery Centre, partner of NANBIOSIS,  has developed a software platform to apply mixed reality to medical training and surgical assistance. This will enable the creation of new and more realistic scenarios for medical training and improve surgical results.

The Minimally Invasive Surgery Centre (CCMIJU) uses mixed reality technology, by means of the Microsoft’s HoloLens glasses, to help train future healthcare professionals and provide an assistance tool for complex surgeries.

The institution located in Cáceres has begun using the mixed reality glasses, whose technology combines virtual reality with augmented reality, with the aim of developing, on the one hand, a medical training platform for the anatomy of the pelvic floor, and on the other, a tool for surgical assistance during renal tumor resection procedures.

The use of this technology will benefit both medical students and residents, as well as surgeons. For the former, a software application has been developed and integrated in the HoloLens glasses, that will allow them to visualize and interact with the human anatomy of the pelvis -with and without pathologies- both at muscular, vascular, bone and nervous systems levels. This will facilitate its translation to the real medical practice.

As for the surgeons, this technology will provide access to preoperative studies and real 3D models of the patient in the form of virtual holograms, facilitating the surgical planning and assistance during the abovementioned renal interventions.

The software, developed entirely at the CCMIJU, is in its validation phase in operating rooms. For the first time, and using their own 3D anatomical models, this type of technology is being used for training on the pelvic floor anatomy and for surgical assistance in renal tumor resections.

This R&D line arises from public-private cooperation. The CCMIJU’s team, led by Dr. Francisco Miguel Sánchez Margallo, Scientific Director of this institution, consists of engineers and staff of the Interactive 3D Unit of the Centre who work together with the company CIBEX on the development of new surgical applications. This alliance will enable healthcare professionals to use this emerging technology in challenging surgical interventions and carry out more effective and safe surgeries.

Read More

Pablo Laguna New Elevated IEEE Fellow for his contributions to cardiac biomedical signal processing

Pablo Laguna, Scientific Director of NANBIOSIS Unit 27, has recently been appointed as a select member (IEEE fellow) of the Institute of Electrical and Electronics Engineers within the society of Medical Engineering and Biology -IEEE-EMBS-.

The grade of Fellow recognizes unusual distinction in the profession and is conferred only by invitation of the IEEE Board of Directors upon a person with an extraordinary record of accomplishments in any of IEEE’s designated fields of interest, in this case, Dr. Laguna is recognized for his contributions to cardiac biomedical signal processing.

The IEEE-EMBSis the world’s largest international society of biomedical engineers. The 11,000 members of the organization reside in some 97 countries around the world. EMBS provides its members access to people, information, ideas and opinions that are shaping one of the fastest growing fields in science.

Pablo Laguna is Professor of Signal Theory and Communications at the School of Engineering and Architecture (EINA) and group leader of the CIBER-BBN and University of Zaragoza research group BSICoS . His work focuses on the search of non-invasive indexes to predict the risk of arrhythmias, the modeling and simulation of cardiac electrophysiology, the evaluation and quantification of the activity of the autonomic nervous system and the processing and characterization of biomedical signals in respiratory pathologies. He has been Scientific Director of the CIBER-BBN from 2011 to 2015.

Read More

Inkjet-Printed Sulfide-Selective Electrode

Gemma Gabriel, Scientific Coordinator of Unit 8 of NANBIOSIS is coauthor of the article  “Inkjet-Printed Sulfide-Selective Electrode” recently publish by ACS Publications in Analitical Chemistry.  Anal. Chem.201789 (22), pp 12231–12236  

DOI: 10.1021/acs.analchem.7b03041

 

 

 

Read More

NANBIOSIS at CIBEREHD XI Annual Conferences

Jesús Izco, Coordinator of NANBIOSIS, has presented NANBIOSIS-ICTS at the XI annual Conference of  CIBEREHD, which takes place from 27 to 28 November 2017 at the Hotel Barceló Sants in Barcelona.

Jesús Izco has explained the opportunities offered by the ICTS NANBIOSIS as a Platform for Research and Biomedical Innovation, giving examples of private-public collaboration in competitive calls  in which NANBIOSIS has participated and explaining the design of the new Nanomedicine Cascade Characterization Service, in which NANBIOSIS is working on.

CIBEREHD (Center for biomedical research in liver and digestive diseases) is

The CIBER’s thematic area of Liver and Digestive Diseases (CIBEREHD) has the purpose of promoting and protecting health by furthering research. This work, whose scope includes both basic research and clinical and translational aspects, is based on the field of Liver and Digestive Diseases with the aim of innovating in the prevention of these diseases and promoting scientific and healthcare progress. At present the CIBEREHD is working on four corporate programmes:

P1. Mechanisms of liver damage/evolution into advanced cirrhosis and transplant.

P2. Gastrointestinal physiopathology: inflammatory illness and motility disorders.

P3. Epidemiology, prevention and treatment of viral hepatitis infection.

P4. Liver and Digestive Oncology

 

Read More

U26-S05. Training Advice and assistance (On-site&Remote)

Training Advice and assistance (On-site&Remote)

Read More

Design of parenteral MNP-loaded PLGA nanoparticles by a low-energy emulsification approach as theragnostic platforms for intravenous or intratumoral administration

Encapsulation of magnetic nanoparticles (MNP) into PLGA nanoparticles has been achieved by nano-emulsion templating using for the first time both, a low-energy emulsification method as well as biocompatible components accepted for pharmaceuticals intended for human use. The incorporation of MNP by nano-emulsion templating method proposed in this work has been investigated in two different systems applying mild process conditions and is shown to be simple and versatile, providing stable MNP-loaded PLGA nanoparticles with tunable size and MNP concentration. MNP-loaded PLGA nanoparticles showed sizes below 200 nm by DLS and 50 nm by TEM, and mean MNP loading per PLGA nanoparticle of 1 to 4, depending on the nanoparticle dispersion composition. Physical-chemical features suggest that the MNP-loaded PLGA nanoparticles obtained are good candidates for intravenous or intratumoral administration.

The equipment of Dynamic Light Scattering (Dynamic Light Scattering) of NANBIOSIS Unit 12 has been used to determine the size distribution of polymer particles and Microscopy with Hyperspectral Analysis (Hyperspectral enhanced dark field microscopy) to detect the encapsulation of magnetic nanoparticles in polymer particles.

Article of reference:

https://doi.org/10.1016/j.colsurfb.2017.09.060

Graphical abstract: Schematic representation of the preparation process of Fe3O4 MHighlightsN P-loaded PLGA nanoparticles by nano-emulsion templating.

Read More
Nanbiosis